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Abstract Purpose:The discovery of novel biomarkersmight greatly contribute to improve clinicalmanage-
ment and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of
endometrial cancer.
Experimental Design: Human kallikrein 6 (hK6) gene expression levels were evaluated in 29
snap-frozen endometrial biopsies, including13 USPC,13 endometrioid carcinomas, and 3 normal
endometrial cells by real-time PCR. Secretion of hK6 protein by 14 tumor cultures, including 3
USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers,
was measured using a sensitive ELISA. Finally, hK6 concentration in 79 serum and plasma sam-
ples from22 healthy women, 20womenwithbenigndiseases, 20womenwith endometrioid car-
cinoma, and17 USPC patients was studied.
Results: hK6 gene expression levels were significantly higher in USPC when compared with
endometrioid carcinoma (mean copy number by real-time PCR, 1,927 versus 239, USPC versus
endometrioid carcinoma; P < 0.01). In vitro hK6 secretion was detected in all primary USPC cell
lines tested (mean, 11.5 Ag/L) and the secretion levels were similar to those found in primary
ovarian serous papillary carcinoma cultures (mean, 9.6 Ag/L). In contrast, no hK6 secretion
was detectable in primary endometrioid carcinoma and cervical cancer cultures. hK6 serum and
plasma concentrations (mean F SE) among normal healthy females (2.7 F 0.2 Ag/L), patients
with benign diseases (2.4 F 0.2 Ag/L), and patients with endometrioid carcinoma (2.6 F 0.2
Ag/L) were not significantly different. In contrast, serum and plasma hK6 values in USPC
patients (6.1 F 1.1) were significantly higher than those in the noncancer group (P = 0.006),
benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005).
Conclusions: hK6 is highly expressed in USPC and is released in the plasma and serum of USPC
patients. hK6 may represent a novel biomarker for USPC for monitoring early disease recurrence
and response to therapy.
Uterine cancer is the most prevalent gynecologic tumor in
women, with an estimated 40,100 cases and 6,800 deaths in the
United States in 2003 (1). Based on clinical and histopatho-
logic variables, two major subtypes of endometrial carcinoma,
namely, uterine endometrioid tumors and uterine serous
papillary carcinomas (USPC), have been described (2, 3).
Although endometrioid carcinomas account for the majority
(i.e., f80%) of cases, these tumors are usually associated with
a history of hyperestrogenism as the main risk factor, are
histologically well or moderately differentiated, and typically
have a favorable prognosis with appropriate therapy. In
contrast, USPCs are poorly differentiated, biologically aggres-
sive tumors, which although account for only f10% of all
endometrial carcinomas are responsible for f50% of all
relapses (4– 12). The discovery of novel diagnostic and
therapeutic markers against this aggressive subset of endome-
trial cancers remains a high priority.
With the goal of identifying genes with a differential pattern
of expression between USPC and ovarian serous papillary
carcinoma (OSPC) and to use this knowledge for the
development of novel diagnostic and therapeutic markers
against this disease, our group has recently used high-
throughput technologies, such as high-density oligonucleotide
arrays, to analyze USPC genetic fingerprints (13). Among the
several candidate target genes identified, the gene encoding
for human kallikrein 6 (hK6 , also known as zyme/protease
M/neurosin) was consistently found as one of the most highly
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up-regulated genes in USPC. The organization of the
kallikrein locus, a gene family now consisting of 15 members
that encode for trypsin-like or chymotrypsin-like serine
proteases, has been elucidated recently (14). Serine proteases
have well-characterized roles in diverse cellular activities,
including blood coagulation, wound healing, digestion, and
immune responses as well as tumor invasion and metastasis
(reviewed in ref. 15). Importantly, secreted serine proteases,
such as prostate-specific antigen, kallikrein 2, and other
kallikreins, have already found important clinical applications
as prostate cancer biomarkers (16). Of interest, hK6 has
recently been found at high levels in the circulation of a
subset of ovarian cancer patients harboring biologically
aggressive tumors (16–18). This discovery has highlighted
the potential of hK6 as a novel biomarker in ovarian cancer
that may have value for disease diagnosis and prognosis. This
report represents the first investigation examining hK6
expression and secretion in human endometrial carcinoma.
Patients andMethods
Primary tumors. Snap-frozen tumor biopsies and tumor samples
were derived from primary specimens staged according to the
International Federation of Gynecology and Obstetrics operative
staging system. Only specimens with >75% tumor content were used
for all experiments. Fresh tumor biopsies from gynecologic tumors,
including 13 endometrioid carcinoma, 13 USPC, 5 OSPC derived
from patients harboring advanced stage disease (III-IV), and 3 cervical
carcinomas from stage IB to IIA patients, were obtained at the time of
surgery through the Gynecologic Oncology Division and the
Pathology Department, University of Arkansas for Medical Sciences
(Little Rock, AR), under approval of the institutional review board.
Patient characteristics from which tumor biopsies were obtained are
described in Table 1. Total abdominal hysterectomy and bilateral
lymph node dissection were done in all endometrial cancer patients.
Normal endometrial control (NEC) cell samples were obtained from
biopsies of benign hysterectomy specimens obtained from women of
similar age. Some primary tumor biopsies (i.e., three USPC, three
endometrioid carcinoma, five OSPC, and three cervical cancer) were
also established as short-term cultures following previously reported
standard tissue culture techniques (13, 19, 20). Briefly, tumor tissues
obtained from cancer patients were mechanically minced and
enzymatically dissociated with 0.14% collagenase type I (Sigma, St.
Louis, MO) in RPMI 1640 as described previously by Santin et al.
(13, 19, 20), respectively. After 1- to 2-hour incubation with enzyme
on a magnetic stirring apparatus at 37jC in an atmosphere of 5%
CO2, the resulting suspension was collected by centrifugation at
100  g for 5 to 10 minutes and washed twice with RPMI 1640
(Sigma) containing 10% fetal bovine serum (Gemini, Woodland, CA).
The final pellet was then placed in RPMI 1640 (Invitrogen, Carlsbad,
CA) containing 10% fetal bovine serum, 200 units/mL penicillin, and
200 Ag/mL streptomycin in tissue culture flasks or Petri dishes
(Corning, Acton, MA). Tumor cells were then allowed to attach and
proliferate. RNA extraction was done at a tumor cell confluence of
50% to 80% after a minimum of 2 to a maximum of 10 passages
in vitro . The epithelial nature and the purity of tumor cultures were
verified by immunohistochemical staining and flow cytometric
analysis with antibodies against cytokeratin and vimentin as described
previously (13, 19, 20). Only primary cultures that had at least 90%
viability and contained >99% epithelial cells were used for hK6
quantification by ELISA as described below.
RNA isolation and cDNA synthesis. RNA isolation from all primary
snap-frozen samples, including 26 primary endometrial cancers (i.e., 13
USPC and 13 endometrioid carcinoma) and 3 normal endometrial cell
controls, was done using TRIzol reagent (Invitrogen) according to the
manufacturer’s instructions. To verify integrity, RNA (4 Ag) from each
sample was run in 1% agarose gel using 18S + 28S rRNA (Sigma) as
positive control. First-strand cDNA was synthesized using 5 Ag total
RNA, 1 reverse transcription-PCR (RT-PCR) buffer, 5 mmol/L MgCl2,
1 mmol/L deoxynucleotide triphosphates, 2.5 Amol/L random hexa-
mers, 1 unit/AL RNase inhibitor, and 2.5 units/AL MulLV reverse
transcriptase (GeneAmp RNA PCR kit, Applied Biosystems, Foster
City, CA) in a total volume of 20 AL. RNA extracted from the CaOV3
serous papillary ovarian cancer cell line, reported previously to express
hK6 (17), was used as a positive control.
Quantitative real-time reverse transcription-PCR. Quantitative real-
time RT-PCR was done with an ABI Prism 7000 sequence analyzer
using the manufacturer’s recommended protocol (Applied Biosystems)
to evaluate expression of hK6 gene in samples from all snap-frozen
biopsies. Each reaction was run in triplicate. The comparative
threshold cycle method was used for the calculation of amplification
fold as specified by the manufacturer. Briefly, total RNA (5 Ag) from
each sample was reverse transcribed using SuperScript III First-Strand
cDNA synthesis (Invitrogen). Reverse-transcribed RNA samples (10 AL;
from 500 AL of total volume) were amplified by using the Taqman
Universal PCR Master Mix (Applied Biosystems) to produce PCR
products specific for hK6. Primers specific for 18S rRNA and
empirically determined ratios of 18S competimers (Applied Biosys-
tems) were used to control for the amount of cDNA generated from
each sample. hK6 primers were obtained from Applied Biosystems as
Assay-on-Demand products.
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Table1. Characteristics of the patients fromwhich primary tumor biopsies were obtained
NEC
(n = 3)
Endometrioid
carcinoma (n = 13)
USPC
(n = 13)
OSPC
(n = 5)
Cervical
cancer (n = 3)
Age (meanF SD) 51F7 58F 15 62F 3 60F 11 40F 6
Stage
I B 10 1 B 3
II B 2 1 B B
III B 1 7 3 B
IV B B 4 2 B
Grading
G1 B 8 B B B
G2 B 3 B 1 2
G3 B 2 13 4 1
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Analysis of hK6 secretion. An important issue is whether hK6 gene
expression differences in tumor tissues result in meaningful differences
in protein expression. To validate hK6 data obtained by RT-PCR on
snap-frozen USPC and endometrioid carcinoma samples at the
protein level as well as to compare hK6 secretion among different
gynecologic malignancies, supernatants obtained from 14 primary
gynecologic tumors, including 3 endometrioid carcinoma, 3 USPC, 5
primary OSPC, and 3 primary cervical cancer, were evaluated by
ELISA. Briefly, tumor supernatants tested for hK6 secretion were
collected by primary tumor cell lines seeded at a density of 1  105
cells/mL in tissue culture Petri dishes in RPMI 1640 supplemented
with 10% fetal bovine serum (i.e., USPC, endometrioid carcinoma,
and ovarian cancer cell lines) or serum-free keratinocyte medium (i.e.,
cervical cancer cell lines). After 48-hour incubation at 37jC, superna-
tants were aspirated, rendered cell-free by centrifugation at 1,500  g
for 10 minutes, and stored at 20jC before being analyzed for hK6
by a ‘‘sandwich’’ ELISA.
hK6 concentration was quantified in the serum and plasma of 22
apparently healthy women, 20 women with benign diseases, 20
women with histologically proven primary endometrioid carcinoma,
and 17 women with histologically proven primary USPC by ELISA as
described previously by Diamandis et al. (21). This assay incorpo-
rates two hK6-specific mouse monoclonal antibodies, one for coating
(clone 27-4) and the other for detection (clone E24) in a sequential
two-site immunometric format with time-resolved fluorescence
detection (21). The assay has a detection limit of 0.05 Ag/L and a
dynamic range up to 20 Ag/L. Variability was <10% with in the
measurement range. Briefly, white polystyrene microtiter plates were
coated with anti-hK6 (27-4) monoclonal antibody (21). Coating
antibody solution [500 Ag/100 AL; 50 mmol/L Tris buffer, 0.05%
sodium azide (pH 7.8)] was added to each well and incubated
overnight at room temperature. The plates were washed thrice with
the washing buffer [5 mmol/L Tris buffer, 150 mmol/L NaCl, 0.05%
Tween 20 (pH 7.8)]. hK6 calibrators or samples (50 AL) and assay
buffer [50 AL; 50 mmol/L Tris, 6% bovine serum albumin, 0.01%
goat IgG, 0.005% mouse IgG (Fortron Bio Science, Inc., Morrisville,
NC), 0.1% bovine IgG, 0.5 mol/L KCl, 0.05% sodium azide (pH
7.8)] were added to respective wells and incubated for 2 hours
with shaking at room temperature. The plates were washed six times
with the washing buffer, after which biotinylated detection anti-
body solution (100 AL; 25-50 ng anti-hK6 (E24) monoclonal
antibody in assay buffer) was added to each well and incubated
for 1 hour at room temperature with shaking. The plates were then
washed six times with the washing buffer. Subsequently, alkaline
phosphatase–conjugated streptavidin solution (5 ng/well; Jackson
ImmunoResearch, Baltimore, PA) in 6% bovine serum albumin
buffer [in 50 mmol/L Tris, 0.05% sodium azide (pH 7.8)] was added
to each well and incubated for 15 minutes with shaking at room
temperature. The plates were washed six times with the washing
buffer, and substrate buffer [100 AL; 0.1 mol/L Tris buffer (pH 9.1)]
containing 1 mmol/L diflunisal phosphate, 0.1 mol/L NaCl, and
1 mmol/L MgCl2 was added to each well and incubated for
10 minutes with shaking at room temperature. Developing solution
(100 AL; 1 mol/L Tris base, 0.4 mol/L NaOH, 2 mmol/L TbCl3,
3 mmol/L EDTA) was added to each well and incubated for 1 minute
with shaking at room temperature. The fluorescence was measured
with a time-resolved fluorometer, the Cyberfluor 615 immuno-
analyzer (MDS Nordion, Toronto, Ontario, Canada).
Patient characteristics from which plasma and serum samples were
obtained are described in Table 2. Serum and plasma samples were
analyzed in duplicate with inclusion of three quality-control samples in
every run. Variability between serum and plasma samples was <0.5 Ag/L.
Of the benign lesions, 12 were classified as endometriosis, 3 as
mucinous cystadenomas, 2 as ovarian dermoid cysts, 1 as ovarian
benign teratoma, 1 as corpus luteum, and 1 as serous cystadenoma.
Serum and plasma samples from all patients were collected before
surgery and stored at 80jC until analysis.
Statistical analysis. Differences among USPC, endometrioid carci-
noma, and NEC in the quantitative RT-PCR expression data were tested
using the Wilcoxon rank-sum test at a = 0.05. The analyses of differences
between hK6 serum and plasma concentrations among the different
groups of patients (i.e., healthy controls, benign gynecologic diseases,
endometrioid carcinoma, and USPC) and among supernatants obtained
from gynecologic tumor cultures with different histologies were done
with the Student’s t test.
Results
hK6 expression in snap-frozen endometrial cancer by quantita-
tive real-time PCR. USPCs are rare tumors that may present in
either pure forms or admixed with endometrioid or clear cell
tumor cells (i.e., mixed USPC; ref. 11). To minimize the risk of
contamination of USPC RNA with that of normal cells or
tumor cells with different histology, we extracted RNA to be
evaluated for hK6 expression by RT-PCR from 26 primary
endometrial cancers with single-type differentiation (i.e., 13
USPC and 13 endometrioid carcinoma). A comparison of the
quantitative RT-PCR data for hK6 in USPC and endometrioid
carcinoma using NEC as controls is shown in Fig. 1. Significant
expression differences between USPC and endometrioid
carcinoma were readily apparent (Fig. 1A and B). All USPC
samples [13 of 13 (100%); mean F SE copy number, 1,927 F
551; range, 111-6,295] and the majority of endometrioid
carcinoma samples [10 of 13 (77%); mean F SE copy number,
239 F 86; range, 1.2-1,184] were found positive for hK6
expression by RT-PCR (Fig. 1B). However, only 1 of 13 (8%) of
the endometrioid carcinoma had a mRNA copy number >350
(Fig. 1B). In contrast, 9 of 13 (69%) USPCs were found to
highly express the hK6 gene with mRNA copy number >350
(Fig. 1B; USPC versus endometrioid carcinoma: P < 0.01). Low
levels of hK6 gene expression were found in the NEC control
cultures tested (mean F SE copy number, 1.2 F 0.2; range,
1-1.5; Fig. 1B).
hK6 secretion by primary gynecologic cancer cell cultures by
ELISA. Snap-frozen biopsies may contain significant numbers
of contaminant stromal cells as well as a variety of host-derived
immune cells (e.g., monocytes, dendritic cells, and lympho-
cytes). Primary short-term tumor cultures, minimizing the risk
of a selection bias inherent in any long-term in vitro growth,
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Table 2. Characteristics of the patients from which
serum and plasma samples were obtained
Variable
Healthy
females
(n = 22)
Benign
diseases
(n = 20)
Endometrioid
cancer
(n = 20)
USPC
(n = 17)
Age (meanF SD) 43F 12 50F 14 62F 10 65F 8
Stage
I B B 16 1
II B B 3 1
III B B 1 10
IV B B B 5
Grading
G1 B B 12 B
G2 B B 6 B
G3 B B 2 17
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may provide an opportunity to study differential hK6 secretion
between highly enriched populations of tumor-derived epithe-
lial cells. Cell-free supernatants from 14 freshly isolated
gynecologic malignancies, including 3 USPC, 3 endometrioid
carcinoma, 5 high-grade OSPC, and 3 squamous cervical
carcinoma, were collected and analyzed for the levels of hK6
expression by ELISA. Because prolonged passages in vitro are
known to alter the physiology and phenotype of primary
tumor cells, we did all our experiments with highly purified
fresh tumor cells grown for <10 passages in vitro . Growth
control medium was always analyzed at the same time. In this
regard, KSFM and RPMI 1640 containing 10% fetal bovine
serum had no detectable endogenous levels of hK6 immuno-
reactivity by ELISA (data not shown). As shown in Fig. 2, all
primary USPC tumor cell lines tested secreted large amounts
of hK6 (mean, 11.5 Ag/L; range, 0.4-26.6 Ag/L/105 cells/48
hours). These levels were not significantly different when
compared with those detected in three of five primary
OSPC cultures used as controls (mean, 9.6 Ag/L; range, 0.0-
26.5 Ag/L/105 cells/48 hours; Fig. 2). In contrast, no hK6
secretion was detected in the three primary short-term
endometrioid carcinoma cultures derived from G2 tumors (1)
and G3 tumors (2) and from the three primary short-term
cervical cancer cultures tested (Fig. 2).
Plasma and serum hK6 concentration in endometrial cancer
and noncancer patients. To investigate whether hK6 is detect-
able in the plasma and serum of patients harboring endometrial
cancer, plasma and serum samples from 20 endometrioid
carcinoma patients and 17 USPC patients were evaluated by
ELISA. In addition, plasma and serum samples obtained from
22 healthy female controls and 20 patients diagnosed with
benign gynecologic diseases were analyzed at the same time.
hK6 serum and plasma levels (in Ag/L) from 22 healthy female
controls (meanF SE, 2.7F 0.2; range, 1.4-4.4), 20 patients with
benign gynecologic diseases (mean F SE, 2.4 F 0.2; range, 1.4-
5.0), and 20 patients with endometrioid carcinoma (meanF SE,
2.6 F 0.2; range, 1.4-4.9) were not statistically significantly
different (Table 3). In contrast, serum and plasma hK6 values in
USPC patients (mean F SE, 6.1 F 1.1; range, 1.9-15.6) were
significantly higher than those in the noncancer (P = 0.006),
benign group (P = 0.003), and endometrioid carcinoma
patients (P = 0.005). The distribution of hK6 concentration in
the four groups of patients is presented in Fig. 3.
Discussion
The discovery of novel biomarkers for the early diagnosis,
monitoring, and prediction of response to treatment in USPC,
the most aggressive variant of endometrial cancer, might greatly
contribute to the improvement of clinical management and
outcomes of these patients. Unfortunately, no accepted and/or
specific serum tumor markers have as yet been identified for
this disease. In this regard, although it has been reported
previously that the elevation of CA 125 level may be associated
with an increase in the incidence of metastatic disease in
endometrial tumors with endometrioid histology (22, 23), this
marker seems to have limited utility in monitoring the effects of
adjuvant therapy or in the prediction of tumor recurrence in
USPC patients (24). This report represents the first evaluation
of hK6, a member of the expanded human kallikrein gene
family (14–16), as a novel biomarker in USPC.
In this study, we have quantified hK6 expression by RT-PCR
in 26 snap-frozen endometrioid carcinoma and USPC speci-
mens. In addition, we have studied hK6 protein secretion in 14
primary gynecologic malignancies, including endometrioid
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Fig. 1. hK6 mRNA copy number by quantitative RT-PCR in 29 snap-frozen
endometrial biopsies. A, hK6 mRNA mean F SE copy number in 3 NEC, 13
endometrioid carcinomas (EC), and 13 USPC. B, hK6 mRNA copy number in
individual NEC controls, endometrioid carcinoma, and USPC samples. For
discussion, see text.
Fig. 2. hK6 levels by ELISA in the supernatants from14 freshly isolated gynecologic
malignancies, including 3 USPC, 3 endometrioid carcinoma, 5 high-grade OSPC,
and 3 squamous cervical carcinomas (CVX).
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carcinoma, USPC, OSPC, and cervical cancer tumor cultures.
We have confirmed the purity of the tumor cells in our short-
term cultures by differential counts of Giemsa-stained cytospin
slides as well as by cytokeratin expression using immunohis-
tochemical techniques (data not shown). Our fresh tumor
samples contained >99% tumor cells. Finally, we have studied
hK6 levels in 79 serum and plasma samples derived from
healthy donors, patients harboring benign gynecologic tumors,
and endometrioid carcinoma and USPC patients.
We report for the first time a high level of expression of the
hK6 gene in USPC. Indeed, hK6 gene expression was
significantly higher in USPC when compared with NEC and
endometrioid carcinoma by RT-PCR. Mean copy number of
hK6 gene mRNA in USPC was 8.1 times higher when compared
with endometrioid carcinoma cells. Consistent with these
findings, highly purified primary USPC cultures were found
to secrete high levels of hK6 by ELISA. In contrast, hK6 was not
detected in any of the three endometrioid carcinoma and three
cervical cancer cell lines tested in this study. Our data highlight
for the first time a major difference between type I (i.e.,
endometrioid carcinoma) and type II (i.e., USPC) endometrial
cancer in the expression and secretion of hK6. Of interest, when
USPC secretion of hK6 was compared with that of primary
OSPC cell lines in vitro, no significant differences were found.
The high levels of hK6 secreted by three of five primary ovarian
tumors tested in our assay are consistent with recent reports
showing high levels of hK6 expression in tumor tissue and
serum of ovarian cancer patients (16, 18, 25). Of interest, in
these recent studies, ovarian cancer patients with preoperative
serum levels of hK6 above 4.4 Ag/L had significantly worse
prognosis than patients with low preoperative hK6 (18).
Furthermore, hK6 overexpression was found to correlate with
intrinsic resistance to adjuvant chemotherapy (18). Taken
together, these data and our own results suggest that high
expression of hK6 in gynecologic serous tumors, regardless of
ovarian or uterine origin, may identify malignancies charac-
terized by an aggressive biological behavior and resistance to
chemotherapy. Consistent with this view, with the single
exception of one patient diagnosed with early stage disease,
all USPC patients evaluated in this study, despite aggressive
adjuvant treatment (i.e., whole pelvis radiation and/or chemo-
therapy), either developed progressive disease during chemo-
therapy or recurred within 1 year after treatment was
completed.
When hK6 levels were quantified in the plasma and serum of
endometrial cancer patients, we found elevated levels in USPC
patients but not in patients harboring endometrioid carcinoma
or benign gynecologic disease when compared with the levels
found in healthy women. Furthermore, in the limited number
of USPC patients where sequential serum samples were
available (i.e., five patients), a decrease in hK6 levels was
observed postoperatively (data not shown). These in vivo data
accord with our in vitro results with highly purified USPC short-
term primary cultures and suggest that this serine protease is
secreted by biologically aggressive USPC cells in vitro as well as
in vivo. In agreement with previous reports (18), we found no
elevation of hK6 in the serum and plasma of patients harboring
benign gynecologic disease or in healthy females. We conclude
that kallikrein 6 is a very promising novel biomarker for early
detection of recurrent USPC disease and for the monitoring
USPC response to adjuvant therapy.
It is worth noting that in our series of USPC patients, all
of whom were surgically staged, the majority were found to
harbor advanced disease. Thus, although most of our patients
were considered to have clinical stage I disease and upgraded
only at the time of comprehensive surgical staging laparot-
omy, it is possible that the elevated levels of hK6 may reflect
a bias related to advanced stage. Although larger studies
including more USPC patients harboring surgically confirmed
early-stage disease will be necessary to exclude this possibi-
lity, it is worth noting that of the two patients included in
this work who had surgically confirmed early-stage disease,
one was found to have elevated levels of hK6. Furthermore,
it is important to point out that because of the propensity of
USPC to rapidly manifest extrauterine disease (i.e., positive
lymph node metastases or spreading to the abdominal
cavity), the USPC series reported here is likely most
representative of the advanced stage disease commonly
found in surgically staged USPC patients. In agreement with
our data, Goff et al. found 75% of patients with clinical
stage I/II USPC to have extracorporeal disease when
comprehensively staged (6). Similarly, Bristow et al. showed
74.4% of USPC patients to have advanced stage disease
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Table 3. Serum and plasma hK6 in noncancer
(healthy), benign disease, endometrioid carcinoma,
and USPC patients
Patient
group
MeanF SE
(Mg/L)
Range
(Mg/L)
Noncancer (n = 22) 2.7F 0.2 1.4-4.4
Benign disease (n = 20) 2.4F 0.2 1.4-5.0
Endometrioid carcinoma (n = 20) 2.6F 0.2 1.4-4.9
USPC (n = 17) 6.1F1.1* 1.9-15.6
*P = 0.006 for noncancer cells versus USCP, 0.003 for benign versus USCP,
and 0.005 for endometrioid carcinoma versus USCP.
Fig. 3. hK6 levels by ELISA in serum and plasma from 22 healthy controls, 20
patients with benign diseases, 20 endometrioid carcinoma, and17 USPC patients.
Horizontal lines, mean values. Noncancer patients versus USPC, P = 0.006; benign
versus USPC, P = 0.003; endometrioid carcinoma versus USPC, P = 0.005 by
Student’s t test.
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following ovarian cancer–type surgical staging (26). These
findings were also corroborated in studies by O’Hanlan et al.
(27) and Geisler et al. (28).
Several other human kallikrein gene family members,
including the enzymes hK4, hK5, hK7, hK8, hK9, and
hK10, have recently been shown to have prognostic
significance in ovarian cancer (14, 15, 29–37). Furthermore,
serine proteases not belonging to the kallikrein family
have also been shown to have prognostic significance in
ovarian cancer, including trypsin, prostasin, hepsin, and
testisin (38–40). Because USPC is histologically similar to
high-grade OSPC, it seems very likely that, in analogy to
ovarian cancer, multiple members of the human kallikrein
gene family may be also dysregulated in USPC. It is thus
possible that other members of this family will emerge as
potential USPC biomarkers. If these proteases are involved in
cancer progression, they may be suitable candidates as
therapeutic targets (41). These possibilities will be investi-
gated in future experiments.
In conclusion, we report here the first evidence that hK6 is
highly expressed in USPC and that high concentrations of hK6
are present in the plasma and serum of USPC patients. Our
results strongly support the hypothesis that hK6 may represent
a novel biomarker for this highly aggressive variant of
endometrial cancer. The current availability of a highly sensitive
and specific immunofluorometric assay for measuring hK6
protein concentration in serum and biological fluids (21) will
facilitate further studies to establish the clinical usefulness of
the circulating levels of hK6 for the management of patients
with USPC.
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